Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-03
2022-502480-38-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + Tiragolumab with Durvalumab (2 arms). Primary endpoints: Progression-free survival (IRF-assessed, PPAS) and Progression-free survival (IRF-assessed, FAS). Started Jul 2024; status: completed.
02
Drugs
atezolizumabtiragolumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502480-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502480-38-00.